GHRP-6 vs Ipamorelin

Side-by-side comparison of GHRP-6, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute GHRP-6 Growth Hormone Releasing Peptide-6 Growth Hormone Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 65
Molecular weight 873.0 Da711.9 Da
Half-life ~15–60 min~2 hours
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining … Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough …
Research status Research Compound Research Compound
Evidence summary GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmac… Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in…
Protocol & Dosing
Typical dose 100–300 mcg per injection100–300 mcg per injection
Frequency 2–3× daily2–3x daily (or 1x at bedtime)
Duration 8–12 weeks8–12 weeks on, 4 weeks off
Timing Fasted state or 2+ hours post-mealFasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse
Safety
Common side effects
  • Significant appetite increase (most common)
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Water retention
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
Contraindications
  • Active malignancy
  • Eating disorders (appetite amplification concern)
  • Hypothyroidism
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, GHRP-2, Hexarelin, CJC-1295 CJC-1295, GHRP-2, Sermorelin, Tesamorelin
Full profile Read full GHRP-6 profile → Read full Ipamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.